Mastectomy for management of breast cancer in Ibadan, Nigeria

Temidayo O Ogundiran, Omobolaji O Ayandipo, Adeyinka F Ademola, Clement A Adebamowo, Temidayo O Ogundiran, Omobolaji O Ayandipo, Adeyinka F Ademola, Clement A Adebamowo

Abstract

Background: Modified radical mastectomy remains the standard therapeutic surgical operation for breast cancer in most parts of the world. This retrospective study reviews mastectomy for management of breast cancer in a surgical oncology division over a ten year period.

Methods: We reviewed the case records of consecutive breast cancer patients who underwent mastectomy at the Surgical Oncology Division, University College Hospital (UCH) Ibadan between November 1999 and October 2009.

Results: Of the 1226 newly diagnosed breast cancer patients over the study period, 431 (35.2%) patients underwent mastectomy making an average of 43 mastectomies per year. Most patients were young women, premenopausal, had invasive ductal carcinoma and underwent modified radical mastectomy as the definitive surgical treatment. Prior to mastectomy, locally advanced tumors were down staged in about half of the patients that received neo-adjuvant combination chemotherapy. Surgical complication rate was low. The most frequent operative complication was seroma collection in six percent of patients. The average hospital stay was ten days and most patients were followed up at the surgical outpatients department for about two years post-surgery.

Conclusions: There was low rate of mastectomy in this cohort which could partly be attributable to late presentation of many patients with inoperable local or metastatic tumors necessitating only palliative or terminal care. Tumor down-staging with neo-adjuvant chemotherapy enhanced surgical loco-regional tumor control in some patients. The overall morbidity and the rates of postoperative events were minimal. Long-term post-operative out-patients follow-up was not achieved as many patients were lost to follow up after two years of mastectomy.

Figures

Figure 1
Figure 1
Numbers of breast cancer patients seen and mastectomies done per year in Surgical Oncology Division, UCH Ibadan in 1999–2009.
Figure 2
Figure 2
Distribution of administration of chemotherapy in 354 patients who had mastectomy in Surgical Oncology Division, UCH Ibadan in 1999–2009.
Figure 3
Figure 3
Neo-adjuvant chemotherapy regimens in 174 pre-mastectomy patients in Surgical Oncology Division, UCH Ibadan in 1999–2009.
Figure 4
Figure 4
Tumour responses to neo-adjuvant chemotherapy in 174 pre-mastectomy patients in Surgical Oncology Division, UCH Ibadan in 1999–2009.
Figure 5
Figure 5
Complications of mastectomy in 51/354 breast cancer patients in Surgical Oncology Division, UCH Ibadan in 1999–2009.

References

    1. Kufe DW, Pollock RE, Weichselbaum RR, editor. Holland-Frei Cancer Medicine 6. 6. Hamilton, Ontario, Canada: BC Decker; 2003.
    1. Zurrida S, Bassi F, Arnone P. et al.The changing face of mastectomy (from mutilation to Aid to breast reconstruction) Int J Surg Oncol. 2011;13:980158.
    1. Adebamowo CA, Ajayi OO. Breast cancer in Nigeria. West Afr J Med. 2000;13:179–191.
    1. El Saghir NS, Adebamowo CA, Anderson BO. et al.Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative. Breast. 2011;13(Suppl 2):S3–S11.
    1. Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg. 1991;13:126–129. doi: 10.1097/00000658-199102000-00006.
    1. Grilli R, Mainini F, Penna A. et al.Inappropriate Halsted mastectomy and patient volume in Italian hospitals. Am J Public Health. 1993;13:1762–1764. doi: 10.2105/AJPH.83.12.1762.
    1. Lee DW, Vallance S. Surgical management of breast cancer in a small peripheral New Zealand hospital. ANZ J Surg. 2006;13:1060–1063. doi: 10.1111/j.1445-2197.2006.03940.x.
    1. El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W. Morbidity and mortality following breast cancer surgery in women: National benchmarks for standards of care. Ann Surg. 2007;13:665–671. doi: 10.1097/01.sla.0000245833.48399.9a.
    1. Anyanwu SN, Egwuonwu OA, Ihekwoaba EC. Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. Breast. 2011;13(Suppl 2):S51–S53.
    1. Adebamowo CA, Adekunle OO. Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg. 1999;13:665–668. doi: 10.1046/j.1365-2168.1999.01117.x.
    1. Clegg-Lamptey JN, Dakubo JC, Hodasi WM. Comparison of four-day and ten-day post- mastectomy passive drainage in Accra, Ghana. East Afr Med J. 2007;13:561–565.
    1. Clegg-Lamptey J, Hodasi W. A study of breast cancer in korle bu teaching hospital: assessing the impact of health education. Ghana Med J. 2007;13:72–77.
    1. Ibrahim NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast. 2012;13:416–418. doi: 10.1016/j.breast.2012.02.006.
    1. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;13:237–249. doi: 10.1053/j.seminoncol.2009.03.001.
    1. Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008;13:1983–1988. doi: 10.1245/s10434-008-9900-7.
    1. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;13:183–188. doi: 10.1007/s10549-007-9694-5.
    1. Gukas ID, Jennings BA, Mandong BM. et al.Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med. 2005;13:209–213.
    1. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y. Breast cancer in Nigeria and Finland: Epidemiological, clinical and histological comparison. Anticancer Res. 2002;13:3005–3012.
    1. Bertheau P, Cazals-Hatem D, Meignin V. et al.Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;13:370–374. doi: 10.1136/jcp.51.5.370.
    1. Olapade-Olaopa EO, MacKay EH, Habib FK. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;13:943.
    1. Murray E. AORTIC Newsletter. South Africa: AORTIC; 2005. Breast cancer clinic at Groote Schuur Hospital; pp. 10–1.
    1. Middleton LP, Chen V, Perkins GH, Pinn V, Page D. Histopathology of breast cancer among African-American women. Cancer. 2003;13:253–257. doi: 10.1002/cncr.11021.
    1. Nichols HB, Trentham-Dietz A, Love RR. et al.Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev. 2005;13:41–47.
    1. Anyanwu SN, Nwose P, Ihekwoaba E, Mbaeri AT, Chukwuanukwu TO. Neoadjuvant chemotherapy for locally advanced premenopausal breast cancer in Nigerian women: early experience. Niger J Clin Pract. 2010;13:215–217.
    1. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer. 2004;13:2512–2532. doi: 10.1002/cncr.20298.
    1. Muss HB, Woolf S, Berry D. et al.Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;13:1073–1081. doi: 10.1001/jama.293.9.1073.
    1. Lee S, Kim SW, Kim SK. et al.Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in korean women with locally advanced breast cancer. J Breast Cancer. 2011;13:289–295. doi: 10.4048/jbc.2011.14.4.289.
    1. Jatol I. Options in breast cancer local therapy: who gets what? World J Surg. 2012;13:1498–1502. doi: 10.1007/s00268-012-1530-3.
    1. Litiere S, Werutsky G, Fentiman IS. et al.Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13:412–419. doi: 10.1016/S1470-2045(12)70042-6.
    1. Pysz M. Blood transfusions in breast cancer patients undergoing mastectomy: Possible importance of timing. J Surg Oncol. 2000;13:258–263. doi: 10.1002/1096-9098(200012)75:4<258::AID-JSO6>;2-I.
    1. Aslan S, Akinci M, Cetin B, Cakmak H, Pirhan Y, Cetin A. Postoperative changes related to intraoperative blood transfusions. Bratisl Lek Listy. 2011;13:575–578.
    1. Leinung S, Schonfelder M, Winzer KJ. et al.Wound infection and infection-promoting factors in breast cancer surgery – a prospective multicenter study on quality control. Zentralbl Chir. 2005;13:16–20. doi: 10.1055/s-2005-836293.
    1. Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish breast cancer cooperative group. Br J Surg. 1991;13:1358–1361. doi: 10.1002/bjs.1800781129.
    1. Akyol AM, Galloway DJ, George WD. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. Br J Surg. 1992;13:470.
    1. Malik H, Bishop H, Winstanley J. Audit of blood transfusion in elective breast cancer surgery–do we need to group and save pre-operatively? Ann R Coll Surg Engl. 2008;13:472–473. doi: 10.1308/003588408X301091.
    1. Ezeome ER, Adebamowo CA. Closed suction drainage versus closed simple drainage in the management of modified radical mastectomy wounds. S Afr Med J. 2008;13:712–715.
    1. Edwards MJ, Broadwater JR, Bell JL, Ames FC, Balch CM. Economic impact of reducing hospitalization for mastectomy patients. Ann Surg. 1988;13:330–336. doi: 10.1097/00000658-198809000-00010.
    1. Purushotham AD, McLatchie E, Young D. et al.Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. Br J Surg. 2002;13:286–292. doi: 10.1046/j.0007-1323.2001.02031.x.
    1. Tarazi R, Esselstyn CB Jr, Kuivila T, Hardesty I. Early hospital discharge following mastectomy. Cleve Clin Q. 1984;13:579–584. doi: 10.3949/ccjm.51.4.579.
    1. Wedgwood KR, Benson EA. Non-tumour morbidity and mortality after modified radical mastectomy. Ann R Coll Surg Engl. 1992;13:314–317.
    1. Yilmaz KB, Dogan L, Nalbant H. et al.Comparing scalpel, electrocautery and ultrasonic dissector effects: the impact on wound complications and pro-inflammatory cytokine levels in wound fluid from mastectomy patients. J Breast Cancer. 2011;13:58–63. doi: 10.4048/jbc.2011.14.1.58.
    1. Kuroi K, Shimozuma K, Taguchi T. et al.Pathophysiology of seroma in breast cancer. Breast Cancer. 2005;13:288–293. doi: 10.2325/jbcs.12.288.
    1. Anyanwu SN. Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J. 2000;13:539–543.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner